Our pipeline
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.
Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.
The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.
For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.
Brand names are trademarks either owned by and/or licensed to GSK or associated companies.
This quarterly pipeline information was updated 01 May 2019.
Key
- †
- In-licence or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.
Pipeline last updated on 01 May 2019
Key
- †
- In-licence or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.
Pharmaceutical pipeline changes from FY 2018 to Q1 2019
Key
- †
- In-licence or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.
Quick Links
Find out more
-
Our approach to R&D
To strengthen our pipeline and deliver the next generation of medicines that we see bringing the greatest value to patients, we have a new approach to Research and Development (R&D).
-
How we develop new medicines
Developing a medicine takes many years. However, rapid advances in science and technology are transforming healthcare, improving the probability of success in R&D, and may help accelerate this process.
-
How we develop new vaccines
We invest in scientific and technical excellence to develop and launch a pipeline of new vaccines that meet the needs of patients and payers.
-
Trials in people
Find out about our clinical trials process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer.
